Genprex, Inc.

04/30/2026

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer: https://ow.ly/abga50YSoya

04/28/2026

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: https://ow.ly/Q3F050YR0Lx

04/24/2026

Genprex collaborators presented preclinical data at in a poster, titled, "Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro." To view the poster, click here: https://ow.ly/gZk750YNAi5 $GNPX

04/23/2026

$GNPX Collaborators presented preclinical data on Reqorsa Gene Therapy in EML4-ALK bearing NSCLC at . Read the poster in more detail here: https://ow.ly/QaeG50YNAbQ

04/22/2026

$GNPX's Chief Medical Officer, Mark Berger, MD, poses with one of our collaborators at the conference. To view the poster, "TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy" in more detail, click here: https://ow.ly/gOas50YNA3J

04/22/2026

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting: https://ow.ly/Vsta50YNUgW

04/21/2026

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy: https://www.genprex.com/2026/04/21/genprex-signs-sponsored-research-agreement-to-study-biomarkers-that-may-predict-patient-response-to-reqorsa-gene-therapy/

04/20/2026

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: https://ow.ly/corz50YMtk7

03/18/2026

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: https://ow.ly/RHlT50YvMYU

03/10/2026

Genprex to Participate at BIO Europe Spring 2026: https://ow.ly/hUQz50YrO02

02/23/2026

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer:

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer February 23, 2026Press Releasesgene therapyLung cancerOncologyReqorsa Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene...